"Inhaled AP01: A Safer and More Effective Alternative for PF Treatment"
Avalyn Pharma's inhaled formulation of pirfenidone, AP01, appears to be more effective and safer than the oral version, Esbriet, for the treatment of idiopathic pulmonary fibrosis (IPF). Data from the Phase 1b ATLAS clinical trial and its open-label extension study showed that AP01 had better efficacy and safety profiles compared to the approved therapy, Ofev, for progressive forms of pulmonary fibrosis (PPF). AP01 is delivered directly to the lungs via a nebulizer, resulting in lower doses and potentially fewer side effects. Avalyn plans to launch a Phase 2 trial of AP01 in PPF patients next year.